GIP, GLP-1, and glucagon receptor agonist
Retatrutide
A triple-receptor investigational peptide with meaningful late-stage human results but no approved product or completed regulatory review.
Also known as RETA · LY3437943 · triple G agonist · triple hormone agonist
01 · Evidence profile
One molecule, four evidence questions
A peer-reviewed phase 2 obesity trial and multiple sponsor-reported phase 3 topline readouts show substantial human outcome signals, while full confirmatory publication and regulatory review remain incomplete.
Human dose-response and adverse-event data exist, but the development program is not complete.
Phase 2 exposure cannot define the full safety profile, rare risks, or long-term benefit-risk balance.
High for documented trial material; low for products marketed outside authorized research.
02 · Identity
What it is
Retatrutide is an investigational agonist of GIP, GLP-1, and glucagon receptors. It is not the same molecule as semaglutide or tirzepatide, and it is not an FDA-approved medicine.
03 · Product identity
The molecule is not the finished product.
Retatrutide is a clinical-development molecule. Trial material made under a study protocol is not evidence that internet products with the same name have the same identity or quality.
None identified in the United States.
- Investigational obesity and metabolic-disease programs
04 · Evidence snapshot
What the evidence can and cannot say
A 48-week randomized phase 2 trial reported dose-dependent weight reduction. In July 2026, Lilly also announced positive topline results from multiple Phase 3 TRIUMPH trials, including defined obesity populations with and without type 2 diabetes or established cardiovascular disease.
Topline disclosures are not a substitute for complete peer-reviewed reports or FDA review. Retatrutide remains investigational, other outcomes programs remain active, and the available records do not establish long-term benefit-risk, rare harms, broad real-world effectiveness, or the identity of material sold outside clinical trials.
05 · Claim check
Three claims under the lens
“Retatrutide caused weight loss in a randomized human trial.”
The phase 2 trial reported dose-dependent weight reduction over 48 weeks in a defined adult population.
- Evidence basis
- Randomized human outcomes
- Scope
- Adults meeting the phase 2 obesity-trial criteria over 48 weeks.
“Retatrutide is FDA-approved.”
It remains investigational. Positive trial results and sponsor announcements are not FDA marketing approval.
- Evidence basis
- Regulatory or product record
- Scope
- United States regulatory status as reviewed July 24, 2026.
“Research retatrutide sold online is the same as clinical-trial material.”
A matching label name does not establish sequence, purity, sterility, formulation, storage, or clinical equivalence.
- Evidence basis
- No reliable human outcome evidence
- Scope
- Products outside an authorized clinical-development supply chain.
06 · Safety boundary
Before this becomes personal
An investigational molecule is not a self-treatment category. This guide does not provide trial-drug access, sourcing, dosing, injection, or combination instructions.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
Reviewed 2026-07-24. This status is not personal clearance to compete.07 · Sources
Check the primary record
08 · Provenance
Review history
Added Lilly's July 2026 Phase 3 topline disclosures and rechecked current investigational and product-status boundaries.
Checked against the phase 2 publication and the June 2026 TRIUMPH-1 registry update: study complete, no summary results posted.
Responsible editor: Anthony Treviso. Editorial source review completed. This page has not been independently medically reviewed by a physician or pharmacist.